AlphAIAlphAI — Financial news for AI agents
investing.comOCT 302 min read$AMRZ

DA Davidson raises Amrize stock price target to $43 on mixed Q3

DA Davidson raised its price target for Amrize (NYSE:AMRZ) to $43, citing mixed Q3 results with strong Building Materials offset by Building Envelope pressure. The stock is up 5.5% weekly but down 22% in six months. Amrize guided below consensus but beat EPS estimates by 2.06% while missing revenue by 0.95%. DA Davidson maintains a Neutral rating, awaiting more execution visibility.

Original reporting
investing.com
Published Oct 30, 2026, 3:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 3:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$AMRZ
Bullish
high confidence
Mentioned
$AMRZ
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AMRZBullishMed
01

Why it matters

The analyst's price‑target increase to $43 reflects belief the stock is undervalued, providing a modest bullish catalyst.

02

Market read

Fresh earnings beat and analyst target raise create a short‑term buying opportunity for traders.

03

What to watch

Potential headwinds from weather‑related volume pressures may limit upside.

Relevance 7/10Novelty 7/10Timing: today

Background

Amrize Ltd (NYSE:AMRZ) posted Q3 2026 results with earnings per share of $0.8717 versus $0.8541 estimate and revenue of $3.13 B versus $3.16 B estimate.

Company-level read

Ticker impact

$AMRZBullishHigh confidence
Context

DA Davidson raised AMRZ price target to $43 and reported mixed Q3 results with earnings beat and slight revenue miss.

Expected impact

likely modest upward pressure as investors digest the target increase and earnings beat.

Evidence & confidence

Analyst upgrade (price target) and earnings beat are fresh, material information for a mid‑cap stock.

Market effects

Sector

Building Materials segment strength may benefit peers in construction materials.

Regional

US construction‑related stocks could see slight lift.

Global

Limited to US equities; no broader macro effect.

Counterpoint

What could challenge this read

Revenue miss and pressure in Building Envelope could weigh on the stock despite the target raise.

Key entities

  • analyst
    DA Davidson

    Equity research firm that raised the price target.

  • company
    Amrize Ltd

    Builder of construction materials reporting Q3 results.

Read at source← All news

Also covered by

4 outlets

Related articles

NOV 1
Med

Amrize Q3 2026 slides: pricing drives margins amid volume headwinds

Amrize reported Q3 2026 revenues of $3.77B, up 2.2% YoY, with net income rising 3.3% to $558M. Pricing initiatives and acquisitions offset volume declines due to weather. Building Materials segment grew 1.8%, while Building Envelope faced challenges. Guidance updated to $12.2B-$12.4B in revenue and $2.95B-$3.05B in adjusted EBITDA for 2026.

investing.com2 min
OCT 30
$AMRZHighAI 9/10

What Amrize (AMRZ) Said on Its Q3 Earnings Call

Amrize (AMRZ) reported Q3 revenue growth of 1.8% to $2.8B in Building Materials and 3.6% to $929M in Building Envelope. Adjusted EBITDA rose 2.7% in Building Materials but fell 14.6% in Building Envelope due to higher costs. The company expects price-over-cost positivity in Building Envelope by 2027. Amrize reaffirmed its 2026 outlook, targeting $12.2B-$12.4B in revenue and $2.95B-$3.05B in EBITDA. It returned $1.1B to shareholders through dividends and repurchases.

finance.yahoo.com3 min
OCT 29
$AMRZMed

Amrize Ltd (AMRZ) Q3 2026 Earnings Call Highlights: Pricing Power Drives Growth

Amrize Ltd (AMRZ) reported Q3 2026 earnings, with revenue and EBITDA guidance updated to $12.2-$12.4B and $2.95-$3.05B. Cement volumes fell 4.2% YoY due to weather, while building envelope EBITDA declined 14.6% from inflation. Price-cost positivity in building envelope delayed to 2027. CEO Jan Jenisch expects 2027 growth but cites inflation and interest rate uncertainties. Free cash flow conversion below 50% target due to higher CapEx.

finance.yahoo.com6 min
OCT 29
$AMRZMed

Amrize (AMRZ) Q3 2026 Earnings Call Transcript

Amrize (AMRZ) reported Q3 2026 earnings, highlighting strong pricing growth and operational efficiency. The company saw solid commercial roofing momentum but softer residential roofing due to lower home sales. Amrize completed $262M in CapEx and acquired PB Materials and Rapid Redi-Mix, strengthening its Texas market presence. The company returned $1.1B to shareholders via dividends and share repurchases, completing a $1B buyback program.

finance.yahoo.com3 min
OCT 29
Med

Why is Amrize stock sliding today?

Amrize AG's stock is down 5.3% in pre-market trading after Q3 2026 results missed revenue expectations and the company lowered its full-year adjusted EBITDA guidance to $2.95–$3.05 billion. Revenue was $3.77 billion, up 2.2% YoY but below consensus. Management cited inflation-driven cost increases. The stock is near its 52-week low.

investing.com2 min